Novo Nordisk shares are trading lower after GLP-1 market competitor Eli Lilly reported Phase 3 results for its retatrutide drug that included statistically significant improvements in weight loss, osteoarthritis pain and sleep apnea.

Novo Nordisk

Novo Nordisk

NVO

0.00
Novo Nordisk shares are trading lower after GLP-1 market competitor Eli Lilly reported Phase 3 results for its retatrutide drug that included statistically significant improvements in weight loss, osteoarthritis pain and sleep apnea.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.